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ABSTRACT
Appropriate inventory management is important for many businesses throughout the world. For the
vaccines industry, appropriate inventory policies impact both the business' profitability and people's
lives. An optimal policy must consider challenges such as product expiration, country specific SKUs, and
a challenging regulatory environment. This thesis discusses an inventory forecasting tool developed for
Novartis Vaccines that that can be used to determine appropriate inventory policies and forecast
resupply needs.
Novartis Vaccines factories ship vaccines to Novartis operated warehouses throughout the world. The
inventory at these warehouses is used to meet customer demand. Each country's warehouse is
responsible for managing its local inventory and forecasting orders to the manufacturing team. Changes
to the forecast can lead to costly manufacturing rework and local stock-outs. Inappropriate inventory
policies can lead to high inventory holding costs and product expiration leading to scrap.
The results of this project show that the best inventory and resupply planning methods differ for
different types of vaccines in different markets. The tool developed looks at differences such as sales
volume and seasonality, distribution methods and costs, product shelf life, and the transfer price to
provide an optimal inventory and resupply forecast. The tool was tested in four countries with several
SKUs in each country and identified approximately 50,000 Euros in savings per country. If the tool was
applied to all 25 countries and similar savings were seen in each country, the organization will save 1.25
Million Euros.
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1. Introduction
Novartis Vaccines' mission states "the only thing better than finding a cure for a disease is
preventing illness in the first place" (1). To succeed in this mission, Novartis needs an end-to-end
supply chain that is prepared to meet customer's needs. They must ensure that the right
vaccine is in the right place at the right time to prevent the spread of illness and ultimately save
lives. Unlike many other supply chains, the vaccine's industry faces several unique challenges.
Two significant challenges are a difficult regulatory environment and a product with a limited
shelf life. These two challenges guide the supply chain practices.
In the past, Novartis Vaccines has focused on improving the manufacturing supply chain: from
raw materials to finished goods within the factory warehouses. To be an industry leader, they
must also focus their efforts on inventory throughout the world and make global strategic
supply chain decisions.
1.1.Novartis Company Overview
Novartis is headquartered in Basel, Switzerland and employs approximately 100,000 associates
in 140 countries. The company focuses on providing "...innovative products to prevent and cure
diseases, to ease suffering and to enhance quality of life" (2). It's broad portfolio of products
range from oncology pharmaceuticals to the influenza vaccine and has one of the most
respected development pipelines (3). It is divided into four key areas (2):
* Pharmaceutics focusing on "innovative patent-protected medicines"
* Sandoz focusing on "affordable, high quality generic medicines and biosimilars"
* Consumer Health focusing on "strong, trustworthy brands for increasing knowledgeable
consumers: OTC (Over-the-Counter), Animal Health and CIBA Vision"
* Vaccines and Diagnostics focused on "vaccines and diagnostic tools to protect against
life-threatening diseases"
1.2.Novartis Vaccines and Diagnostics
Novartis Vaccines and Diagnostics was established in April 2006 when Novartis acquired Chiron.
It is headquarter in Cambridge Massachusetts and in 2009 had net sales of $2.5 billion. The
Vaccines business has a global presence, with manufacturing facilities in Germany, Italy, the
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United Kingdom, India, and the United States. Novartis Vaccines supplies influenza, travel, and
meningitis vaccines to nearly every continent (1).
1.3.Thesis Motivation
In the past several years, Novartis Vaccines has begun to switch from a third party distribution
system to managing its own inventory in locations worldwide. They have warehouses in over
20 countries which are used to meet the needs of customers in that country. Figure 1 illustrates
how vaccines move from the factory (manufacturing) to the local country warehouses to the
end customer. Notice that product stored in one country cannot ship to another country's
customers. This is because the product is often country specific. If customers in Country B want
a vaccine that is in Country A, the product must return to the factory (or a 3rd party) where it is
relabeled and repackaged. At this point, it can ship to Country B's warehouse. This time
consuming process prevents customers from receiving the right vaccine at the right time. As a






Figure 1. Distribution model
Each country's organization has a Commercial Operations team which is responsible for
identifying and forecasting the local customer demand. These sales forecasts look at an 18-
month time horizon and are re-evaluated and updated each month. Using their sales forecast
and information about the inventory they have in their local warehouse, they develop a
resupply plan. The resupply plan is a request from the country's Commercial Operations
organization to the Manufacturing organization to provide a given quantity of vaccines in a given
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week of the year. Figure 2 shows a simplified version of how a typical country organization may
develop a resupply plan assuming it is currently December of 2010. In this example, forecasted
inventory is calculated using Equation 1.
List of variables
1j =Forecasted inventory in month j
FSj = Forecasted sales for month j
Rj= Resupply plan for month j
Calculate Inventory in month j+1
'1+1 = Ij + Rj - FSj
Equation 1. One country organization's method for forecasting inventory
SKU ABC12345
FY2011 Jan-11 Feb-11 Mar-11 Apr-1I May-11I Jun-11 Jul-11 Aug-11I Sep-11 Oct-11 Nov-11 Dec-11
Sales forecast 2,000 2,500 3,000 4,000 4,500 7,500 8,000 8,000 8,000 6,000 3,000 2,000
Forecasted inventory 10,000 28,000 25,500 22,500 38,500 34,000 26,500 18,500 10,500 22,500 16,500 13,500
Resupply plan 20,000 20,000 20,000
FY2012 Jan-12 Feb-12 Mar-12 Apr-12 May-12 Jun-12
Sales forecast 2,500 3,000 3,000 5,000 5,500 8,000
Forecasted inventory 11,500 29,000 26,000 23,000 38,000 32,500
Resupply plan 20,000 20,000
Figure 2. Example of how one country may develop their resupply plan
Each country's Commercial Operations organization develops their resupply plan using different
methods. Each unique method has various advantages and disadvantages; however, no method
has been consistently successful. For example, non-optimal resupply planning methods have led
to scrapping of inventory due to expiration of product, last minute requests for products from
the manufacturing organization, and non-optimal inventory levels.
1.4.Project Objective
The goal of this research is to develop a standardized method that each country's Commercial
Operations organization can use to determine the optimal resupply plan. This standardized
method should help country organizations:
e Reduce excess inventory
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e Reduce scrap and right-of-returns
e Reduce inventory and distribution costs
e Reduce last minute requests to the manufacturing organization
By improving the inventory and resupply planning methods used, the country organizations will
improve their profits and their ability to supply customers with the vaccines they need.
1.5.Research Methodology
The challenges faced by the vaccines industry are common among distribution organizations.
Many companies have warehouses worldwide that supply local customers with goods. They
must forecast sales and develop inventory and resupply methods that meet those sales needs.
As a result, we can develop best practices for vaccines by understanding methods used
throughout other industries and modifying them to meet the unique challenges of the vaccines
industry. To develop the optimal inventory and resupply planning methods, we had a five step
process.
Step 1: We started by conducting a literature review. The information gathered in this
process allowed us to benchmark other industries and identify potential methods.
Step 2: We interviewed stakeholders within the Novartis Vaccines organization focusing on
people within manufacturing distribution and logistics, commercial operations sales force,
and commercial operations resupply planners.
Step 3: We formed a small team of country resupply planners. This team represented the
country organizations that would be a part of the initial pilot of the model and would
provide valuable insight throughout the development of the model.
Step 4: We began the modeling process. Data was collected from both the manufacturing
and commercial organizations. Frequent feedback from the pilot team was used to refine
the model.
Step 5: We piloted the model in four countries. The data collected provided model
validation and assessment for potential roll-out to the entire organization.
1.6.Thesis Outline
This document is organized into 5 chapters:
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* Chapter 1 provides an introduction to Novartis Vaccines and a brief description of the
problem motivation and objective.
e Chapter 2 introduces inventory and resupply planning methods used throughout
industry. It explains the specific challenges faced by the vaccines industry and explains
Novartis Vaccines' current methods for developing resupply plans.
e Chapter 3 describes the model and tool developed. It explains when the model is most
useful as well as some of its limitations.
e Chapter 4 validates the model through the use of three case studies.
* Chapter 5 closes the thesis with conclusions and recommendations.
15 1 P a g e
2. Inventory and Resupply Planning Management
2.1. General Inventory and Resupply Calculation Methods
Inventory and resupply planning is based on several factors. The various methods used
throughout industry differ mainly by how a resupply is triggered and the size of the resupply (in
most literature, resupply is referred to as an order but for purposes of this thesis, the term
resupply will be used). The most common policies are related to a few specific decision
variables: resupply point (RSP), review interval (R), resupply quantity (Q), and resupply level (L).
In a R,L policy (review interval, resupply level), resupply is dependent on the review interval (R).
The resupply quantity is determined by the quantity required to make current inventory equal
the resupply level (L). If resupply is placed every review interval, this is called a base-stock
policy. This type of policy is applicable when there is periodic review of inventory and when the
resupply quantity can be any value.
In a RSP,L policy (resupply point, resupply level), resupply is triggered by inventory reaching the
resupply point (RSP). Similar to the R,L policy, the resupply quantity is determined by the
quantity required to make current inventory equal the resupply level (L). This type of policy is
applicable when there is a continuous review of inventory and resupply orders can be placed at
any time. Additionally, it applies when the resupply quantity can be any value.
In a RSP,Q policy (resupply point, resupply quantity), resupply is triggered by inventory reaching
the resupply point (RSP). The resupply quantity is determined by a set of factors that is
independent of current inventory levels. This type of policy applies when there is continuous
review of inventory (4).
The method chosen for this research is a modified RSP,Q policy and the basic methods for
determining RSP and Q are discussed below in Sections 2.1.1 thru 2.1.3.
2.1.1. Safety Stock
Safety stock is inventory kept to manage variability in demand. When variability in demand is
high, a higher level of safety stock is maintained. When there is no variability in demand no
safety stock is required. Equation 2 defines safety stock levels (5). It assumes that demand over
different time intervals are independent.
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List of Variables
Z = a value which corresponds to the desired inventory service level
GD = the standard deviation of demand during a single period
T = lead time
Calculate Safety stock (SS)
SS = Z x O- X NT
Equation 2. Generalized safety stock equation
2.1.2. Resupply Point
The resupply point is the inventory level which signals a resupply order. This value takes into
account the consumption of the item during the lead time. The lead time is the time from when
the order is placed until the order is received. Equation 3 defines the resupply point (5).
List of Variables
LTD = lead time demand. It is the future demand during the lead time
SS = safety stock
Calculate Resupply Point (RSP)
RSP = SS + LTD
Equation 3. Resupply point equation
2.1.3. Resupply Quantity
The resupply quantity is the number of units which should be forecasted when the resupply
point is reached. Ideal resupply quantities are based on balancing inventory holding costs and
order costs. This quantity is called the economic order quantity (EOQ) and is discussed further
in Section 3.2.3.1.
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2.2. Challenges for the Vaccines Industry
The general methods described in Section 2.1 apply to many industries including the vaccines
industry. However, there are several challenges in the vaccines industry that must be
understood in order to correctly apply and modify these methods.
2.2.1. Shelf Life
Similar to food, electronics, medical drugs, and human blood, vaccines are perishable and
therefore have a shelf life (6). Perishable inventory policies can result in lower safety stock
levels than normal inventory policies due to the cost associated with disposing of stock.
Additionally, resupply quantities are often lower than EOQ because they must consider the shelf
life of the product (7). Infinite lifetime inventory policies can be applied in two scenarios:
product shelf life is long or there is little variance in demand (8).
2.2.2. Regulatory
The regulatory environment for vaccines products impacts inventory and resupply policies. For
example, each receiving country has different requirements for the product packaging such as
languages, regulatory labels, ect. This impacts production; they must customize the product
during the fill/finish process to meet the specific countries needs. Product customized for one
country may not meet the regulatory requirements of another country. As a result, if demand
changes, and the product is no longer required by the original country, the product may need to
be re-packaged or scrapped. Therefore, it is critical the country specific demand does not
change after the fill/finish process has begun. When there is demand in a specific country the
resupply lead time associated with this fill/finish process must be considered so an order can be
placed with sufficient time.
In additional to manufacturing fill/finish limitations, countries have various release protocols.
When product arrives at the receiving country, it may require testing by the local regulatory
agency. This process can take from 1 day to 3 months and can entail checks on verifying correct
labeling, verifying that the cold chain was maintained, ect. As a result, this also significantly
impacts the resupply lead time.
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2.2.3. Service Level
Service level is a method used to measure the performance of a system. There are several
definitions when considering the service level provided by inventory. Some common definitions
include the probability that there will be no stock outs within an order cycle or a percent
demand that can be satisfied by stock (5).
The service level requirements in the vaccines industry are often higher than that in other
industries because vaccines save lives. Due to this, the cost of not meeting demand is not only a
monetary factor but also a social factor. This challenge leads to high safety stocks for many
types of vaccines.
2.2.4. Product Type
Vaccines products can be divided into three major categories based on their inventory and
resupply policies.
* Seasonal influenza vaccines (also referred to as seasonal flu vaccine) are vaccines that
combat the three most common influenza viruses for the upcoming season (9). Each year, a
new seasonal influenza vaccine is produced. As a result, last year's product is not sellable
this year and must be scrapped.
e Emergency vaccines are those required for rare but serious illnesses. The regulatory
environment for these vaccines is often different than that for other vaccines. For example,
for many vaccines in this category a single stock-keeping unit (SKU) can satisfy demand in all
countries. As a result, inventory for every countries' demand can be pooled and product
designated for one country's demand can be shifted to meet another country's demand
quickly.
* All other vaccines are those that do not fall into the categories listed above. These types of
vaccines include those for rabies, hepatitis, measles, mumps, polio, smallpox ect. Inventory
for these vaccines face the challenges described in Section 2.2.1, 2.2.2, and 2.2.3. These
types of vaccines are the focus of this research.
2.2.5. Demand Variations
Demand for vaccines in each country differs significantly based on several factors. Demand is
significantly impacted by the protocols in each country. For example, one country may require
that all school age children receive a specific set of vaccines while another country has no
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requirements. Similarly, seasonal volume can vary. In the example above, the country that
requires school age children to receive a specific set of vaccines will likely see a peak in demand
right before the school season begins. These seasonality effects differ for each country and
impact inventory and resupply policies.
2.3. Novartis Vaccines Methods
2.3.1. Sales and Operations Planning Process
Country inventory and resupply planning at Novartis Vaccines is accomplished through a robust
Sales and Operations Planning (S&OP) process which repeats monthly. During this process the
commercial and technical operations organizations work together to determine how to balance
supply with demand. Figure 3 depicts the demand and supply planning process. The interaction
between demand and supply is shown in red.
m I I Combined E
'LI~d ~.l Country RoalResupply eupyrqst ImanufacturingLocaoca Resupp y Rsumpa requtest
~
Tt~ouJ lan rom all regions
Commercial Operations Responsibility e pens 00 t
Figure 3. Demand and supply planning process
There are four phases to the S&OP process:
1. Demand Phase: Each country and/or region is responsible for determining their needs from
the technical operations organization for the next 18 months. In order to determine this,
they look at their expected sales in the local market. Additionally, when there are country
warehouses, they use information about the local inventory. Using this information,
commercial operations develops a resupply plan. This resupply plan is a forecast of their
future orders. This resupply plan is communicated to the technical operations organization
through the rolling forecast which is uploaded into SAP and is used during the next phase.
Improving this process is the focus of this research.
2. Supply Phase: Once the demand phase is complete, the technical operations team reviews
the demand and develops a supply plan for each manufacturing site. Any situations where
manufacturing is unable to meet demand are identified.
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3. Global S&OP Meeting Phase: All the supply plans are combined and presented. Any
discrepancies between the demand phase and the supply phase are discussed. Any issues
that are not resolved will be escalated to the final phase.
4. Executive S&OP Phase: The supply plans are presented to the executive committee. Any
issues that have not been resolved in the previous phases are resolve at this time. If
necessary, the supply and rolling forecast are updated accordingly.
2.3.2. Demand Phase Current State Analysis
The demand phase is accomplished using different methods. Most countries commercial
operations teams are responsible for developing their resupply forecast and entering this into
the rolling forecast. Figure 4 depicts countries which operate with a Novartis business unit.
Figure 4. Countries operating with a Novartis business unit
In the countries colored in green, inventory is managed by a Novartis business unit and the
country's commercial operations team is responsible for developing a resupply plan that is
entered into the rolling forecast.
Since each commercial operations team in each country operates independently, each country's
business unit used a different method to develop a resupply plan. In February 2010, there were
three primary methods:
1. Based on demand and current inventory: This was the most common method used. The
sales and marketing team in the country forecast sales for each vaccine for the next 18
months. The resupply planner for the country enters these forecasted sales into an excel
table which includes current inventory levels. The sales and marketing team, resupply
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planner, and financial team then decide how large of resupply orders they wanted and the
timing of these resupply orders. This represents the resupply plan. Once they develop the
resupply plan, they enter the data into the rolling forecast for the technical operations team
to view. Figure 5 shows an example of this method for a country.
Vaccine X
FY2010 Jan-10 Feb-10 Mar-10 Apr-10 May-10 Jun-10 Jul-10 Aug-10 Sep-10 Oct-10 Nov-10 Dec-10
Sales forecast 2,000 2,500 6,000 4,000 1,000 7,500 1,000 1,000 1,000 1,000 Z000 4,000
Forecasted inventory 10,000 18,000 15,500 9,500 15,500 14,500 7,000 16,000 15,000 24,000 23,000 31,000
Resupply plan 10,000 10,000 10,000 10,000 10,000 10,000
Coverage* 3 4 5 4 6 15 6 8 4 4 3 4
FY2012 Jan-11 Feb-11 Mar-11 Apr-11 May-11 Jun-1I Jul-11 Aug-i1 Sep-11 Oct-I1 Nov-11 Dec-11
Sales forecast 8,000 10,000 8,000 5,000 2,000 2,000 2,000 1,000 1,000 1,000 1,000 2,000
Forecasted invento 37,000 29 000 19,000 11,000 6,000 4,000 12,000 10,000 9,000 8,000 7,000 6,000
Resupply plan - 10,000
Coverage* 6 7 7 6 4 3 12 8 7 5 4 N/A
*Coverage defined as forecasted inventory divided by the average sales forecast in the upcoming four months. Many countries had a goal of
always having at least 3 months of coverage
Sales Goal FY2010 27,000
Sales Goal FY2011 46,000
Figure 5. Current state resupply planning process based on demand and current inventory.
Each commercial operations team that uses this method has a different internally developed
spreadsheet to help them with resupply planning. Frequently, this spreadsheet does not
track expiration dates. This leads to vaccines being scrapped because they reached their
expiration date. Additionally, this spreadsheet does not include factors such as shipping
costs, minimum resupply quantities, and lead times.
2. Based on demand, current inventory, and MRP: Rather than develop spreadsheets as shown
in the "demand and current inventory" method, some commercial operations teams use
MRP systems to help them do resupply planning. At Novartis, the MRP system utilizes the
sales forecast and current inventory to develop a resupply plan. The resupply order is
forecasted when inventory drops below a specific threshold. The resupply order size as well
as the inventory threshold is set when the MRP system is implemented or when it is
manually updated.
This method has some advantages and disadvantages relative to the "demand and current
inventory" method. Often, the resupply quantity that is set in the MRP system is
determined through a discussion with the technical operations team. This results in a
resupply quantity that is reasonable; at least at the time it is implemented. The major
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disadvantage of this method is that many commercial operations teams set the inventory
threshold to a given value without considering how different vaccines require different
inventory thresholds. Additionally, the values set in the MRP system are rarely reviewed.
As a result, the values are often out-of-date and are no longer representative of best
practice.
3. Based on demand only: Although uncommon, some commercial operations teams utilize
only their sales forecast to develop a resupply plan for each product. Instead of looking at
current inventory, they utilize historical knowledge to determine when a resupply is
required. They then enter this resupply plan into the rolling forecast.
This method has all the flaws that the "demand and current inventory" method has but has
additional problems. Since there is no review of current inventory, inventory levels can be
very high and a lot of capital can be tied up in inventory. Additionally, with no review of
inventory, space can be an issue. These issues demonstrate that there are significant
savings if the right inventory and resupply planning policies are established.
Each commercial operations team conducts resupply planning in a different way. There is
limited sharing of best practices between the country commercial operations teams. A
standard practice for developing resupply plans will benefit both commercial operations and
technical operations. It will improve their ability to meet customer demand reliability at the
lowest cost.
2.4. Chapter Summary
There are several methods that can be used to do resupply planning. A common method for
resupply planning is based on determining the resupply point and resupply quantity. Although
this method works well for many industries, it does not meet all the needs of the vaccines
industry. Vaccines products have shelf lives and are sold in highly regulated environments.
They save lives and as a result need to have very high service levels. The demand for vaccines is
impacted by local regulations as well as seasonal fluctuations. Resupply planning must consider
the type of vaccine: seasonal influenza vaccines, emergency vaccines, or all other types of
vaccines. Since each of these types of vaccines requires different policies, the analysis
presented in this paper is focused on the "other" category.
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Novartis Vaccines has a robust Sales and Operations Planning process which repeats monthly. It
has four stages: demand phase, supply phase, global S&OP phase, and executive S&OP phase.
The focus of this analysis is on the demand phase. During the demand phase, each country
develops a resupply plan for each SKU it orders looking at an 18-month horizon. This resupply
plan is entered into the rolling forecast which technical operations use to plan manufacturing.
Each country's commercial operations team uses a different method to do resupply planning
and each method used has flaws. By improving resupply planning methods, customer demand
will be met more reliability at a lower cost.
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3. Model
3.1. Introduction
Country commercial operations teams need a model to help them improve their resupply
planning. The model must consider the major supply chain factors for the vaccines industry and
then recommend a resupply plan which can be entered into the rolling forecast.
The model is based on a modified resupply point and resupply quantity methodology, initially
discussed in Section 2.1. Figure 6 depicts the generalized theory. In Figure 6 the safety stock is
100 doses, the resupply point is 140 units and the resupply quantity is 100 doses. Forecasted in-
country released inventory depletes every month when forecasted sales are made. When the
forecasted in-country released inventory reaches the resupply point, a resupply is forecasted.
Using Figure 6 as an example, the resupply plan should include 100 doses in months 2 and 7 (see
Figure 7). This would be communicated to the technical operations team through the rolling
forecast. The technical operations team would then develop a manufacturing and supply plan
that would lead to 100 doses arriving at the country warehouse at the beginning of months 2
and 7. When the doses arrive, they are unreleased inventory. The warehouse performs steps
such as quality inspections to release the inventory and make it available for sale. In the
example shown in Figure 6, this in-country release process takes 2 months.
25 1 P a g e
In-country releaseda I (-utr rv IeadU and un-releaised In -ountry
forecasted inventory forer aste~d inventory .- releaise timeResupply quantity







Resupply Point - When oo
forecasted inventory is Resupply quantity of 100 units
projected to reach this / I is released in-country
level, a resupply order
should be forecasted
0
0 2 4 6 8 10 12
Month
Safety Stock - planned inventory never drops below the safety stock. The purpose of
safety stock is to satisfy variability in demand
Figure 6. A basic example showing forecasted inventory
Resuplply Plan
Month I1 I2 I3 I4 I5 I 6 I7 I8 I9 I10 11i
Resupply 0 100 0 0 0 0 100 0 0 0 0
Figure 7. Resupply plan for example in Figure 6
Although Figure 6 depicts safety stock, resupply point, and resupply quantity as constant values
this is a simplification and does not always apply. Due to the challenges in the vaccines industry
described in Section 2.2, these values can change. As a result, the safety stock, resupply point,
and resupply quantity must be calculated at some defined time interval. For Figure 6 above, the
inventory is being monitored monthly (the review interview is monthly) and thus a monthly time
interval is sufficient. The analysis from here on assumes that the appropriate time interval is
monthly however this model can be adapted for any time interval
3.2. Model Calculations
3.2.1. Safety Stock
Safety stock is kept to manage uncertainty in demand. As demand uncertainty changes with
time, the safety stock must also change. To forecast future safety stock requirements, we must
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develop a method to understand the changes in demand uncertainty with time. To accomplish
this, we define the following:
e Seasonality Factor (SEm): The Seasonality Factor is used to express predictable changes in
sales that happen every year. m is the month of the year and ranges from 1 to 12 where 1 is
January and 12 is December. For example, a vaccine's sales may increase by a factor of 2
every August and September. Thus, the SE8= SE9= 2. In this example, all other seasonality
factors equal 1.
* Market Dynamics Factor (MS;): The Market Dynamics Factor is used to express expected
changes (growth or reduction) in market demand. j is the number of months from present.
For example, if it is January 2011 now and it is expected that sales will double in February
2011 and remain doubled, MSo=1 and MS1 .=2.
Using these definitions, we calculate the standardized past sales for month j (PSS;).
List of Variables
PS; = the past sales for month j
SEm = the seasonality factor for month m
MSj = the market dynamics factor for month j
Calculate standardized past sales (PSSj)
PS-
PSSj = sP SEm x MS;
Equation 4. Standardized past sales equation
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Using the standardized past sales, we can calculate the standard deviation of standardized past
sales (opss). We assume that opss for a given month is associated to changes in sales that result
from SEm and MS and calculate the past sales standard deviation standardized to the month j
(PSC). In this equation, we estimate the standard deviation of SEm and MSj to be the square root
of SEm and MSj respectively based on the assumption of independent time increments.
List of Variables
opss = standard deviation of standardized past sales
MSj = the market dynamics factor for month j
SEm = the seasonality factor for month m
Calculate past sales standard deviation standardized to month j (PSC;)
PSCj = Uess x MSx f5-
Equation 5. Past sales standard deviation standardized to month j equation
In order to complete the calculation for safety stock, we must also calculate the safety stock
lead time (SSLT), the lead time factor (LTF), and the service factor (SF).
List of Variables
RT = in-country release time
RP = review period. This is the frequency that the resupply plan and rolling forecast is updated.
TF = the time fence. This is the time the organization can react to a change in the rolling
forecast. For vaccines products, this is often the time it takes to make a generic product (ie
meningitis vaccines) be a specific SKU (meningitis vaccine for the United States).
SL = inventory service level. This is discussed further in Section 2.2.3
CNDF[X] = the cumulative normal distribution function of X
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Calculate safety stock lead time (SSLT)
SSLT = RT + RP + TF
Equation 6. Safety stock lead time equation
Calculate lead time factor (LTF)
LTF = SSLT
Equation 7. Lead time factor equation
LTF in Equation 7 estimates the standard deviation of the SSLT to be the square root of SSLT.
Calculate service factor (SF)
SF = CNDF[SL]
Equation 8. Service factor equation
Using the calculations above, we calculate the safety stock (SS;).
List of Variables
PSCj = past sales standard deviation standardized to the month j
LTF = lead time factor
SF = service factor
ESS = emergency safety stock. This value is set by the organization.
Calculate safety stock (SSj)
SS = PSC xLTF xSF+ ESS
Equation 9. Safety stock equation
Using Equation 9 we can forecast the future required safety stock. This will be used to forecast
the resupply point.
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3.2.2. Resupply Point
The resupply point (RSPj) triggers a forecasted resupply. To calculate the resupply point, we
must first calculate the resupply lead time (RLT) and the lead time demand (LTD;).
List of Variables
RT = in-country release time
RP = review period
FSj = forecasted sales for month j
SSj = safety stock for month j
Calculate resupply point lead time (RLT)
RLT = RT + RP
Equation 10. Resupply point lead time equation




Equation 11. Lead time demand equation
Calculate resupply point for month j (RSPj)
RSP = SS; + LTD
Equation 12. Resupply point equation
Equation 12 calculates the resupply point assuming there is only variability in demand. This is a
simplification of reality. Often, there is also variability in supply and this must be included when
determining the safety stock and resupply point. If there is no data available on the variability
of supply, we can increase the resupply point by a buffer equal to some number of months of
demand. This will be the method used to calculate the resupply point with an additional supply
buffer (RSPBj).
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List of Variables
SB = months of supply buffer
RSPj = resupply point for month j
Calculate resupply point with a supply buffer (RSPBS)
SB+j
RSPB = RSP + FS;
I
Equation 13. Resupply point with a supply buffer equation
3.2.3. Resupply Quantity
The next critical step is determining what resupply quantity should be forecasted when the
resupply point is reached. The resupply quantity is based on one of four calculation methods:
1. Total costs (QTc) - this method minimizes the ordering costs and inventory holding costs to
result in lowest total costs.
2. Shelf life (Qshelflife)- this method considers the forecasted sales (FSj) and the sellable shelf life
of the product to decrease the likelihood of scrapping product.
3. Minimum packaging quantity (QmpQ) - this method considers the limitations of
manufacturing and is the least number of a given SKU that can be supplied.
4. Resupply frequency (Qreq) - this method considers a desired order frequency.
It is important to note that methods two and three above assume each resupply has the same
sellable shelf life. For example, a resupply forecasted in March 2011 will have 12 months of
shelf life and a resupply forecasted in May 2011 will also have 12 months of sellable shelf life.
Since these products will have different expiration dates, it implies that these two supplies are
from different batches.
Method four above was developed to manage situations where recommended orders were
more frequent than the organization desired. Qi.q is greater than QTc and decreases the
resupply frequency. It is used when the corporation decides that resupply must occur at a
frequency less than some maximum. QTc fails to meet this criteria when the organization has
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underestimated the order and inventory costs. When ordering and inventory costs have been
accurately accounted for Qfreq is not necessary.
Figure 8 shows the logic used to determine which method for calculating the resupply quantity
is appropriate. This logic is used for each month which the resupply point is reached. For each
month j, the logic is evaluated at i:
i = i + RLT where RLT is the in-country release lead time
Equation 14. Resupply quantity evaluation month i
Equation 14 allows us to forecast a resupply in month j for release in month i that is the
appropriate quantity for month i.
Figure 8. Logic for determining resupply quantity
The first step in the logic is to determine if Qrc is less than Qsheflife. This step determines if
product shelf life is a limiting factor that should impact the resupply quantity. The second step
is to determine if QTc is greater than QmpQ. This step determines if the minimum packaging
quantity may be a limiting factor. Step 3a evaluates if QTc is greater than forecasted sales in
month i (FS,). If it is greater than one month of sales, a resupply quantity of QTc is
recommended. If Qrc is less than one month of forecasted sales, then Qreq is the resupply
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quantity. This logic assumes a maximum resupply frequency of monthly; however, slight
modifications to the logic can make it apply to any maximum resupply frequency.
Step 3b determines if Qsheiflife is greater than QmpQ. This step determines if Qhente is an
acceptable order quantity from the manufacturing organization. When Qshefiife is less than QmpQ,
the resupply quantity is QmPQ. When this occurs, we expect that some product will expire prior
to being sold and thus will be scrapped.
3.2.3.1. Total Cost Resupply Quantity
The standard method for calculating a resupply quantity is based on total costs. This
method minimizes the total inventory holding and ordering costs. Ordering costs are fixed
costs that are generally independent of the order quantity. Inventory holding costs are
variable costs and they are correlated with the order quantity. Figure 9 shows an example
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Figure 9. Recommended order quantity based on total costs
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List of Variables
D = monthly demand of product (in Figure 9, D=100 units)
F = fixed cost per order (in Figure 9, F=$10)
C = cost per unit (in Figure 9, C=$100)
H =cost of capital (in Figure 9, H=5%)
Q = order quantity (in Figure 9, Q is on the X-axis and ranges from 0 to 55 units)
Calculate total costs (TC)
TC = OrderCost + HoldingCost
FxD HxCxQTC= +Q 2
Equation 15. Total costs equation
If we minimize the total costs, we calculate the economic order quantity (EOQ) as shown in
Equation 16 (5).
2 x Monthly Demand x Fixed Order Cost
EOQ = F Monthly Holding Cost Per Unit
Equation 16. Economic order quantity equation
For vaccines products, order costs are significantly impacted by the cost of specialized
shipping containers. In general, one of two sized shipping containers is used. Each shipping
container has a fixed cost associated with renting and using the container for a set period of
time. Additionally, the cost of shipping the container is independent of how full the
container is. As a result, there are two separate order costs depending on which shipping
container is used. Additionally, each shipping container has a specified volume such that
there is a maximum amount of product that fits in each type of container. This complication
means additional analysis is required to determine the best resupply quantity.
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We will assume that the two shipping container sizes are Si and S2 with order costs of K, and
K2 respectively. We will assume that Si< S2<2 X Si and that K1 < K2<2 X K1. As a result, there
are three scenarios which must be considered:
Scenario A. Si < EOQ - Shipping container 1's capacity (Si) is less than the economic order
quantity for shipping container 1 (EQ 1). This scenario can occur in 4 different ways.
This is depicted in Figure 10 thru Figure 13 .The recommended order quantity for this
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Figure 10. Scenario A where S, is the best order quantity
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Total cost of the economic order
quantity for S2 is less than the total
cost of S1. As a result, the economic
order quantity associated with
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Figure 11. Scenario A where EOQ2 Is the best order quantity
Total cost of S2 is less than total
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Figure 12. Scenario A where S2 is the best order quantity
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Figure 13. Scenario A where S is the best order quantity
Scenario B. EOQ 1 <S < EOQ 2 - The economic order quantity for shipping container 1 (EOQ 1 )
is less than shipping container 1's capacity (Si) and shipping container 1's (S1) capacity is
less than the economic order quantity for shipping container 2 (EO 2 ). This scenario is
depicted in Figure 14. The recommended order quantity for this scenario is EOQ 1 .
$500
$450 
- Total cost of the economic order
$400 quantity for S, is less than the total
$350 -- cost of the economic order quantity S2 -As a result, the economic order
$300 quantity associated with shipping
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Figure 14. Scenario B where EOQ1 is the best order quantity
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Scenario C. Si < EOQ2 - Shipping container 1's capacity (Si) is less than the economic order
quantity for shipping container 2 (EOQ 2). This scenario is depicted in Figure 15. The
recommended order quantity for this scenario is EOQ 1.
Total cost of the economic order
quantity for S, is less than the total
cost of the economic order quantity S2-
As a result, the economic order
quantity associated with shipping


















Figure 15. Scenario C where EOQ1 is the best order quantity
The analysis shown in Figure 10 thru Figure 15 is simplified into the decision diagram in
Figure 16. This logic is used for each month which the resupply point is reached. For each
month j, the logic is evaluated at i as discussed in Equation 14.
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S,= Doses per smaller (or only) shipping container
S2= Doses per larger shipping container
K1 = Order costs for smaller (or only) shipping container
K2 = Order costs for larger shipping container
EOQ = Economic Order Quantity for smaller (or only) shipping
container
EOQ 2 = Economic Order Quantity for larger shipping container
TCEOQ 2 = Total costs for EOQ2 -
TCS1 = Total costs for smaller (or only) shipping container
TCS2 = Total costs for larger shipping container
Figure 16. Logic for determining QTc
3.2.3.2. Shelf life Resupply Quantity
Since vaccines products expire, it is important to consider a resupply quantity that reduces
the likelihood of scrapping product. We must determine the sellable shelf life which is
dependent on the shelf life of the product and the customer's shelf life requirements.
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Equation 17 through Equation 19 calculate the sellable shelf life (SSL), the forecasted sales
over the sellable shelf life (A) and the resulting recommended resupply quantity based on
shelf life (Qshelffife).
List of Variables
DSL = average shelf life upon product arriving in-country
SLC = remaining shelf life required by the customer
RT = in-country release time
FS, = forecasted sales for month i where i is calculated based on Equation 14.
PSC5 = past sales standard deviation standardized to month j (reference Equation 5)
ASS= average safety stock
Calculate sellable shelf life (SSL)
SSL = DSL - SLC - RT
Equation 17. Sellable shelf life equation
Calculate forecasted sales over the sellable shelf life (A)
SSL+i
A = FSn
Equation 18. Forecasted sales over the sellable shelf life equation
Calculate the resupply quantity based on shelf life (Qhelflfe)
Qshelf life = A - 2 x PSC; - ASS
Equation 19. Resupply quantity based on shelf life equation
Qsheffife is a conservative resupply quantity that reduces the likelihood of product expiring. It
takes the forecasted sales over the sellable shelf life (A) and decreases this quantity by two
standard deviations of sales (PSC;). This reduces the resupply quantity enough such that if
sales are two standard deviations lower than forecasted, the resupply quantity does not
expire before it is sold. We also must subtract the average safety stock (ASS). If we did not
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subtract the ASS, and if actual sales were two standard deviations below forecasted sales,
we would have to scrap the safety stock. By creating a conservative estimate of Qshelflife, we
reduce the likelihood of scrapping product. This strategy does have one major
disadvantage. If sales are higher than forecasted, we will need to change the resupply plan
to include another resupply order to prevent a stock-out.
3.2.3.3. Minimum Packaging Resupply Quantity
Many organizations require a minimum quantity be purchased at a given time. This is often
referred to as the minimum order quantity. For vaccines products, this is often dependent
on manufacturing process and is limited by the number of vaccines of a specific SKU that can
be packaged efficiently at one time. As a result, the minimum packaging quantity (QMPQ) is
determined by the organization and his highly dependent on the processes used within the
organization.
3.2.3.4. Frequency Resupply Quantity
Although the three resupply quantities (QTc, Qshelflife, and QMPQ) are theoretically sufficient to
determine the ideal resupply quantities, practically, these may not be sufficient. Often, an
organization does not want internal orders to occur faster than a specific frequency. As a
result, we use a resupply quantity based on frequency (Qfrequency).
Qfrequency is highly dependent on the organizations needs. For Novartis Vaccines, the
frequency was set to monthly - resupply should be provided at a maximum of once a
month. Additionally, it was determined that the resupply quantity should optimize the use
of the shipping containers whenever possible. We determined that full shipping containers
should be used whenever the shipping container size is between one and three months of
forecasted sales. As a result, the logic in Figure 17 is used to determine the appropriate
Qfrequency-
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List of Variables
S1 = Doses per smaller (or only) shipping container
S2 = Doses per larger shipping container
sCC, = Shipping cost per smaller (or only) shipping container
sCC2 = Shipping cost per larger shipping container
Fsj = forecasted sales for month i
Assumptions
This logic assumes you will always ship in either S,
or S2 containers and never use a combination of
both S, and S2. This assumption is made to prevent
the creation of an optimization problem that would
disrupt performance of the model in excel.
Determines if a multiple of full
container of size 1 is between 1
month and 3 months of demand
Determines least number of full
shipping containers of size S, to
satisfy 1 month of the forecasted
sales in month i
Shipping in full containers results in
shipping more than 3 months of
forecasted sales. As a result, one
month of forecasted sales is the
resupply quantity.
Determines if a multiple of full Determines least number of fullMathematical symbol container of size 2 is between 1 shipping containers of size S2 tomeans round up to month and 3 months of demand satisfy 1 month of the forecastnearest integer
Figure 17. Logic for determining Qf,
3.2.3.5. Rounding Resupply Quantity
The calculations for the resupply quantity discussed in sections 3.2.3.1 through 3.2.3.4 have
no rounding rules. Since vaccines come in boxes, it is often ideal to ship a full box rather
than a partially filled box. Additionally, there may be benefits to shipping a full container or
a full batch. As a result, users of the model enter percentages for when they would like
their order rounded up or down to the nearest box, shipping container, and manufacturing
batch. For example, say a box contains 100 doses and the resupply quantity determined
based on the calculations in sections 3.2.3.1 through 3.2.3.4 indicates an order size of 1,122
doses. If the user enters into the model that the order sizes should be rounded down to the
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nearest box when less than 25% of a box is full, the model will suggest ordering 1,100 doses
instead of 1,122 doses.
3.2.4. Inventory
In order to generate the resupply plan, we must track inventory levels and forecast when
the resupply point is reached. This is done using Equation 20 to calculate inventory levels.
List of variables
Ij =Inventory in month j
FS; = forecasted sales for month j
Ej = Inventory that expires in month j
Rj= Inventory received in month j
Calculate Inventory in month j+1
i+ 1 = I; + R; - FS; - E;
Equation 20. Inventory Equation
3.3. User Interface
In order for the resupply planning model to be easy to use, it is embedded into an excel tool.
This excel tool has three major sections: inputs, calculations and results. Each month, the user
enters the inputs into the tool. The calculations discussed in Section 3.2 are done on hidden
tabs. The recommended resupply plan as well as potential cost saving information is displayed
in the results tabs. For each SKU in each country, a separate copy of the tool is required.
3.3.1. Inputs
There are three input tabs in the excel tool. Inputs 1 is for planning data, Inputs 2 is for sales
data, and Inputs 3 is for country and product data. The Inputs 1 tab has a feature to advance to
the next planning period. This is accomplished through a macro called "Next Planning Period".
The code for this macro is detailed in Appendix B.
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Throughout the inputs tabs, three different colored backgrounds are used as described in Figure
18. By color coding the excel tool, users clearly understand what they must do each month.
Appendix A shows the input tabs.
White colored cells should not be changed
eachooredclls should be reviewed at least every 3
months and ulldated as reoured
Figure 18. Description of input tab background colors
3.3.2. Calculations
Calculations are completed on two hidden tabs in the excel tool. These tabs are called
Calculations SS,ROP,Q and Current Inventory Forecast. These tabs contain all the equations
expressed in Section 3.2.
3.3.3. Results
The results are displayed to the user in several ways. The first is a results summary tab called
Result. On this tab the user can look at the recommended resupply forecast and the resulting
inventory forecast. This tab also provides the user cost information allowing the user to make
cost trade-off decisions.
The Result Details tab provides the user with additional information. On this tab, the user is told
which resupply quantity the model chose (reference Section 3.2.3 for details). It also displays
the results if rounding was not allowed. This tab allows the user to further understand the
impact of the inputs they enter. Appendix A shows these tabs in more detail.
The Scenario Analysis tab provides users with an easy method to modify parameters and
compare results. This is done via a macro called "Save a Scenario". The VBA code for this macro
is displayed in Appendix B.
3.4. Model Usefulness
The model developed helps commercial operations evaluate their inventory forecast and
develop a resupply plan. It is most beneficial when:
* Sellable shelf life of the product is short. In this case, the model provides a resupply plan
that limits the scrapping of product.
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e Current inventory is at risk for expiring prior to sale. Often, the sellable shelf life of a vaccine
is overlooked and this leads to unplanned stock-outs and emergency orders. The model
tracks current inventory and provides a resupply plan that considers expiration of current
inventory.
e Resupply quantities can be optimized to shipping container and/or manufacturing batch
sizes. In many cases, the commercial operations team does not know the number of doses
in a shipping container or in a manufacturing batch so they do not know how to plan
resupply quantities optimally. Using the model, resupply quantities can be optimized to
match the manufacturing and distribution process.
* Sales forecast is uncertain and various scenarios need to be analyzed. Often, the
commercial operations team assumes a single sales forecast and does not consider various
scenarios because they do not have an easy way to think about the various outcomes. The
model allows for easy comparison of these scenarios helping the commercial operations
team develop a more robust resupply plan.
e Cost of holding inventory is high or cost of shipment is high. In these cases, the resupply
quantities or inventory should be optimized to decrease overall costs. The model weighs
these factors effectively to save the organization money.
3.5. Model and Tool Limitations
Although the model and tool provide a large improvement over the current resupply planning
practices, it has several limitations. These key model limitations are:
e The resupply plan optimizes inventory levels and resupply quantities based on in-country
information. It assumes that the only inventory buffer is the country warehouse. In reality,
inventory buffers are also held in various stages of the manufacturing process and this
should impact the amount of inventory and the resupply plan of the country's commercial
operations organization.
" When resupply quantities are calculated by total costs, the resupply quantity is very
sensitive to the order costs and the cost of holding inventory. These pieces of data are
difficult to obtain and inaccuracy leads to inefficiencies in the resupply plan.
e When resupply quantities are calculated by shelf life, the accuracy of the forecasted sales is
critical. If sales fall below that of the forecasted sales, there is a risk of scrapping product.
To reduce the likelihood of this, the user should consider various scenarios and consider
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using resupply quantities associated with the lowest sales forecast. This will decrease the
likelihood of scrapping product, however, it will likely increase ordering costs.
e The model is sensitive to the data entered for seasonality and market trends (SEm and MSJ).
If this data is inaccurate, safety stock levels will be inappropriate and can lead to stock outs.
* For forecasted and past sales, users must identify when outliers exist and decide when it is
appropriate to include them or exclude them. For example, if the government makes a
predicted very large one time purchase, this quantity should either be excluded from the
sales history or it should be included and reflected in the market trends factor. In contrast,
if the government makes an unpredicted very large one time purchase, this quantity should
be included in the sales history and not reflected in the market trends factor. In the first
case the sale should not impact the safety stock level while in second case the unpredictable
sale should impact the safety stock level.
e New products have no past sales data. As a result, the safety stock cannot be calculated. In
this case, the user must decide a safety stock level. Since this safety stock level is based on
the user's intuition, it may be too high leading to high inventory costs or too low resulting in
stock outs.
* When large quantities of inventory will expire, the recommended resupply plan's resupply
quantity may not be optimal. For example, if inventory will drop to 0 doses due to an
expiration of a batch, the resupply plan may include a resupply quantity optimized for total
costs (QTC); however; this quantity may not be sufficient to raise the inventory level above
the resupply point. This is a consequence of using a resupply quantity as oppose to a
resupply level methodology discussed in Section 2.1.
The major limitations of the tool are:
e The tool requires a different excel workbook for each SKU in each country. When a
commercial operations organization is responsible for a resupply plan for 10 different SKUs,
the tool may be confusing and cumbersome.
e The tool requires more inputs than the current methods use and as a result can be more
time consuming to develop a resupply plan.
e The tool requires manual inputs of data that is located in the ERP system. This is both time
consuming and can lead to transcription errors.
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3.6.Areas for Improvement
As discussed in Section 3.5, there are several aspects of the model and tool which could be
improved. We will discuss the most impactful potential improvements.
The model developed focuses on inventory which is held at the warehouses in each country. It
does not consider the inventory at the factories, nor does it consider inventory at warehouses in
other countries. Usually, inventory from one country's warehouse cannot be sold to customers
in another country; however, this is not always the case. Since the model only considers
inventory in a specific country we have not developed a system wide optimal inventory policy.
A multi-echelon inventory optimization would result in a more optimal policy (10); however,
such a policy requires information to flow freely between the country commercial operations
organizations and the technical operations organization. This requires these pieces of the
organization to use the same MRP system and also operate with the same underlying business
objectives. Since Novartis Vaccines does not currently operate on a single MRP system, this
method is not currently feasible. As Novartis Vaccines transitions to a single MRP system, a
multi-echelon approach should be considered.
This model is based on a resupply point, resupply quantity (RSP,Q) policy; however, a resupply
point resupply level policy (RSP,L) may be preferable in specific situations. Since the review
period for Novartis Vaccines is relatively frequent (monthly), these two policies usually have
similar results. The major difference occurs when large quantities of inventory are scrapped due
to expiration. In this case, a resupply policy based on a resupply level would be more optimal.
The model could be updated for these cases.
The model determines safety stock based on variability of sales in the past 6 months and the
corresponding market and seasonality trends. Ideally, safety stock would be determined by the
accuracy of the sales forecast. At the time of this research, Novartis Vaccines did not have a
viable method for tracking accuracy, however it was under development.
Finally, the model should be incorporated into the MRP system such that manual data entry is
not required. Under the current system, country commercial operations teams must obtain
information from the MRP system as well as from external excel spreadsheets in order to
complete the input tabs of the tool. This results in a redundancy of work and makes the tool
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less user friendly. Integrating the model with the MRP system will improve the user-friendliness
of the tool.
3.7. Summary
We have developed a model that considers all the major factors for resupply planning for
vaccines products. The model uses a resupply point and resupply quantity methodology to
create a resupply plan.
The resupply point calculation is based on safety stock and lead time demand; both of which
vary through time as forecasted future sales change and as seasonality and market dynamics
vary.
The resupply quantity is based on a decision tree and is correlated to total costs (QTc), shelf life
(shelflife), minimum packaging quantity (QmpQ), or resupply frequency (Qfrequency). The model
allows rounding of the resupply quantity to optimize to full boxes, shipping containers, and/or
manufacturing batches. Like the resupply point, the resupply quantity may constantly change.
In order to determine when the resupply point is reached, inventory levels must be forecasted.
This is accomplished by considering the expected sales, resupply, and expiration of vaccines.
When the forecasted inventory reaches the resupply point, a resupply is forecasted and entered
into the resupply plan.
The model was embedded into excel to create a user interface that is easy to use. The user
interface is divided into three sections: inputs, calculations, and results. The user enters
information into the inputs section. Model calculations are hidden from the user to provide a
more user-friendly interface. The result section provides the user with a recommended
resupply plan and a corresponding inventory forecast.
The model developed is especially useful when a product has a short shelf life, when order
quantities and inventory levels can be optimized, and when scenario planning is necessary.
Despite this, there are several model limitations many of which could be addressed by creating a
common MRP system.
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4. Model Validation
4.1. Methodology
In order to validate the model, we identified four Novartis country organizations that had
varying levels of success with inventory management. We chose countries throughout the
world: two in the Europe, one in South America, and one in North America. The variation in
location provided a wide range of SKUs as well as significant variation in input parameters, such
as transfer price. Additionally, country selection was based on data availability. We chose
countries where information for all three input tabs was available and had resupply planners
who were interested in improving their inventory and resupply planning methodologies.
We collected all the required information for the model. We then compared the model's
recommended resupply plan with the country's most recent resupply plan. We thoroughly
analyzed the model's recommendation to verify its feasibility and practicality.
4.2. Limitations of our approach
Although we believe this validation methodology represents the best feasible option, there are
limitations associated with this approach. The validity of the input data is important. Since this
was the first time anyone was asked to think about several parameters, the data may not be as
accurate as desired. For example, resupply planners had never considered seasonality and
market dynamics trends in the way the tool requires. Additionally, inventory holding costs and
inventory service levels were terms not commonly discussed. As a result, historical trends in
sales were studied to identify seasonality and market fluctuations and determine the
appropriate values for the seasonality factor (SEm) and the market dynamics factor (MSj).
Additionally, the cost of capital was estimated and the same value was used for all country
organizations.
4.3. Case Studies
To demonstrate the validity and effectiveness of the model, we will discuss three cases. The
results from these cases are real; however, the data has been altered for confidentiality.
4.3.1. Case 1: Long Shelf Life with Minimal Sales Fluctuation
Some vaccines products have long shelf lives relative to their demand. In these cases, the shelf
life of the product is not an issue and resupply quantities are based on total costs, frequency, or
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minimum packaging quantities. In one example, forecasted sales are constant at 30,000 doses
monthly with no predicted seasonality or market fluctuations. As a result the safety stock and
resupply point are also constant. A data set for this case and the resulting resupply plan and
inventory forecast are shown in Appendix C.
In this sample case, the recommend resupply quantities are based on total costs (QTc) and the
larger shipping container size (S2). The resupply plan generated by the country's commercial
operations organization results in significantly higher inventory levels. Additionally, the resupply
quantities are larger than a single shipping container resulting in significantly higher ordering
costs. By changing the resupply plan to match that of the model, the organization can save over
100,000 Euros annually.
In this example, the model developed is more complicated than necessary. Since shelf life and
minimum packaging quantities do not play a role in this example, the calculations discussed in
Sections 2.1.1 through 2.1.3 for RSP, SS, and EOQ are sufficient for developing a resupply plan.
Despite this, the tool provides an easy method for developing a resupply plan. As a result, even
in the simplest of cases the tool helps the organization with resupply planning.
4.3.2. Case 2: Short Sellable Shelf Life
Several products have a short sellable shelf life. These products are at risk of expiring before
they are sold, which is very costly for the organization. In one example, sellable shelf life is 6
months and forecasted sales are constant at 1,000 doses monthly with no predicted seasonality
or market fluctuations. There is a current inventory of 10,000 doses that expires 8 months from
now. A data set for this case and the resulting resupply plan and inventory forecast are shown
in Appendix C.
In this example, the resupply quantity is based on the shelf life (Qshelflife). The current inventory is
expected to expire before being sold and, as a result, the model's recommended resupply plan
includes a resupply the month current inventory expires. The country's commercial operations
organization did not notice the vaccine would expire prior to being sold. Consequently, their
resupply plan results in a stock out when the product expires. Additionally, the resupply
quantities chosen by the country's commercial operations organization result in each resupply
expiring prior to being sold. By following the model's resupply plan, scrapping costs are
minimized.
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In this case, the model provides a resupply plan that helps the organization manage the short
shelf life product. Ideally the model would estimate the cost of scrapping product when
following the resupply plan developed by the commercial operations team. This could be easily
added in the next revision of the model.
4.3.3. Case 3: Seasonal and Market Trends
Several products have fluctuating sales throughout the year. This fluctuation is expected and is
often referred to as seasonality trends. In this example, students are usually vaccinated within
the first few months of the school year and this results in a predictable increase in sales during
this time period.
Additionally, changes in the market are often predictable and therefore should be planned for.
In this example, next year the government will require all students be vaccinated. This results in
an expected increase in sales when the policy takes effect.
The model considers this predicted variation to be systematic rather than random. As a result,
the model changes the safety stock and resupply points according. The details for this example
are shown in Appendix C.
The Commercial Operations team's resupply forecast considers these factors by increasing
resupply frequency when the new government policy takes effect. As shown in Section 9.3, the
team's resupply forecast results in higher annual costs than the model's recommendation due
to this increase in resupply frequency. Rather than increasing the frequency, the model
increases the resupply quantity optimizing the use of the shipping containers. The result is a
savings of over 16,000 Euros annually.
4.4. Summary
The model and tool were validated using several case scenarios. We discussed three primary
case scenarios: product with a long shelf life and minimal sales fluctuations, product with a
short sellable shelf life, and product with seasonal and market trends. In all case studies, the
tool showed improved inventory and resupply methodologies.
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5. Conclusions and Recommendations
A model and tool to improve inventory forecasting and resupply planning practices was
presented in this thesis. The tool was piloted in four country organizations and proved useful
for all scenarios tested. It is based on a modified resupply point, resupply quantity methodology
and considers factors such as product seasonality, product expiration, and desired inventory
service levels. The tool is designed for a system which has a monthly review period and an 18
month planning horizon. It considers optimal resupply quantities based on ordering and
inventory holding costs, product sellable shelf life, minimum packaging quantities, and a
maximum order frequency. The tool was tested in four countries with several SKUs in each
country and identified approximately 50,000 Euros in savings per country. If the tool was
applied to all 25 countries and similar savings were seen in each country, the organization will
save 1.25 Million Euros.
5.1. Model Refinement
As discussed in Section 3.6, there are several areas for improvement in the model and the tool.
A multi-echelon system would decrease inventory and distribution costs to the organization;
however, the current ERP systems prevent this from being a feasible option. Since ERP changes
are not currently feasible, the single-echelon model should be further refined to use a resupply
point, resupply level policy when inventory expiration is an issue. Additionally, the costs section
of the tool should be improved to include costs associated with expiration of product. This
modification would provide a more accurate representation of resupply plan costs. For further
information on model refinement see Sections 3.5 and 3.6.
5.2. Organizational Alignment
Accuracy of the input data in the model is critical for its success. Currently, each country
determines their sales forecast using different methods. Additionally, there are no incentives in
place to reduce inventory costs or to provide accurate resupply plans to the technical operations
organization. As a result, the country organizations carry significant amounts of inventory and
change their resupply plans each month. By developing metrics and incentives focused on sales
forecast accuracy, inventory costs, and resupply plan accuracy the commercial operations
organizations in each country would be better aligned with the technical operations
organization. This alignment would improve the supply of vaccines to each country. Ultimately,
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this would increase Novartis Vaccines and Diagnostics revenue and provide vaccines to more
patients.
5.3. Tool Usability
The tool was developed using an interactive approach with frequent feedback from future users.
This resulted in a user interface which reflects the preferences of the pilot team. In order for
the tool to be a success, this iterative process must be continued. As the tool is rolled-out to
additional users, their feedback regarding ease of use and interface improvements should be
incorporated into the tool.
5.4. Potential Savings
By piloting the tool in four countries, we were able to evaluate the potential savings of
improving resupply planning and inventory management practices. For some SKUs,
implementation of the tool did not have a large impact. In these examples, product expiration
was not an issue and the resupply quantities chosen by the resupply planners were near
optimal. In other cases, large improvements were identified. In the four countries piloted, the
tool identified an average savings of 50,000 Euros per country. If the tool was applied to all 25
countries and similar savings were seen in each country, the organization will save 1.25 Million
Euros.
5.5. Implementation
One of the largest challenges was implementation of the tool. With over 25 potential users in
different countries, training and tool maintenance was an unsurpassable hurdle for Novartis.
With a non-integrated MRP system and no common network, the organization was unable to
break this barrier to allow complete implementation of the tool. Despite this, the organization
did successfully role out training which taught the resupply planning teams the concepts of
safety stocks, resupply points, and resupply quantities. This training, based on the concepts
presented in this thesis, provided resupply planners the tools to make inventory and resupply
planning decisions to reduce scrap of short sellable shelf life product and decrease inventory
holding costs. Although the training will not lead to optimal inventory and resupply planning
policies, it will be a large improvement over current practices.
If Novartis or another organization wishes to implement this tool, a champion must be identified
that can answer questions and address problems. If a country's commercial operations
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organization is unable or unwilling to dedicate the resources to setting up the tool this
champion should estimate parameters, run the data set in the tool, and provide generalized
feedback to the country's resupply planners. This approach will provide the commercial
operations organization an idea of how large their resupply orders should be and what safety
stock should be carried. This will likely reduce stock-outs and lower inventory holding costs and
demonstrate the impact of good inventory and resupply planning practices.
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7. Appendix A: The Novartis Resupply Planning Tool User Interface
The following screenshots comprise the Novartis Resupply Planning Tool developed in Excel.
7.1. Inputs 1
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Plannina Data for Vaccine X
General Information:
Planning for Month/Year Sp1




Invenry at the begini of Au-2010
I patch I at at h3
Number of Doses
Expiration Date
Deliveries expected or requeded in 10
Number of Doses
Expiration Date
Go To Next Planning
Peritod
7.2. Inputs 2
Sales Data For Vaccine X
Do you have Sales Data for the Lad 6 months? Yes
Previous Sales
Date Feb-10 Mar-10 Apr-10 May-10 Jun-10 Jul-10
[doses]
Are there repeatable annual trends es
Repeatible Annual Trends [mu tipi er)
Month Jan Feb Mar Apr May I Jun Jul Aug Sep Oct
Multipler
Are there market changes? Yes
Change In Market Dynamics [multiplier)
Date Feb-101 Mar-101 Apr-101 May-101 Jun-101 Jul-101 Aug-101 Sep-101 Oct-10 Nov-10
MLtiplier 1
Enter the forecasted sales for the next 18 months
DateI Sep-101 Oct-101 Nov-101 Dec-101 Jan-111 Fet-111 Mar-11I Apr-11l May-111 Jun-11l
Dec-10 -Jan-il Feb-li Mar-li1 Apr-iI May-il Jun-il Jul-li Aug-li Sep)-li Oct-l I Nov-l Dec-il Jan-12 Fb1
IJul-ill Aug-ill Sep-ill Oct-ill Non-ill Dec-ill Jan-121 Feb-i21
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7.3. Inputs 3
Country and Product Data for
Daa on this sheet should be reviewedat least every three months to
coiirm It's accuracy
Data on this sheet was last reviewed on
In-Country Release Time and Coats
In County Release Time [months)
Non-Variable In-Country Release Costs per Order [Euros]
Tech Ops Times and Costs
Time Fence [months]
Tech Ops Non-Variable Order Processing Costs [Euros]
Shof Life Requirements
Standard Shelf Life when prodict reaches country [months
Remaing shef life requ red by customer [months]
Annua nventory Holding Cost
Minimum Packaging Quantity
Transfer Price per dose [Euros]
Dentory Srvice Level Des red
Desired Supply Buler [months]
Does this product require a extra safety stock due to
emergency outbreaks?
Container Size and Shipment Cost Information
Do you recieve shipments in diferent size shipping
containers depending on the order quantity?
Smaler Larger
Container Container
Maximum doses per shipping container
Non-Variable Cot [Euros]
Do you prefer shipments of full boxes?
Doses Per Box
Do you prefer shipments of full Containers?
Do you prefer shipments of full batches?
Doses per Batch Size?
Rounding Rules
Round Down
if order size Round up if
is this order size is
percent this percent
greater than less than a
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7.4. Results
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8. Appendix B: Visual Basic for Applications Code




'Create message box and confirm user wants to continue
MessageContinue = "You can not undo this action. Do you want to Continue?"
response = MsgBox(MessageContinue, vbExclamation + vbYesNo + vbDefaultButton2)
Select Case response
Case Is = vbNo
Exit Sub
End Select
'Change "Planning for Month Year" cell
Dim NextMonth As Date
NextMonth = DateSerial(Year(Cells(4, 2).Value), (month(Cells(4, 2).Value) + 1), 1)
Cells(4, 2).Value = NextMonth



















ActiveSheet.PasteSpecial Format:=3, Link:=1, DisplayAsIcon:=False,















ActiveSheet.PasteSpecial Format:=3, Link:=1, DisplayAsicon:=False,
Icon File Name:=False
'Return to Inputs 1 tab
Sheets("Inputs 1").Select
End Sub
8.2. Save a Scenario Code
Sub SaveAScenerioo
'SaveAScenerio Macro
' Keyboard Shortcut: Ctrl+Shift+A
'This Macro copies and pastes data (not functions) from the result worksheet to the Scenerio
Analysis worksheet
'Define worksheets
Dim ResultWorksheet As Worksheet, ScenarioAnalysisworksheet As Worksheet
Set ResultWorksheet = ThisWorkbook.Worksheets(" Result")
Set ScenarioAnalysisworksheet = ThisWorkbook.Worksheets("Scenario Analysis")
Dim ResultsInformation As Range
Set ResultsInformation = ResultWorksheet.Range("2:29")
'Copy and Paste values from Results page
ResultsInformation.Copy
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9. Appendix C: Case Studies
9.1. Data for Case 1: Long Shelf life with Minimal Sales Fluctuation
Country and Product Data for Long Shelf life With
Minimal Sales Fluctuation
Planning Data for Long Shelf life With Minimal Sales,
Fluctuation
Plannin for MonthWYear S I
First Week of Month 35
Country LrSeffl
Data on this sheet was last reviewed on
In-Country Release Time end Combs
rnC a s Time [months] 0 ena ble in-Country Reirs ts per Order Euros)
Tech Ops Times and Codte
Tam Fence Fmonthsl 
4Tech Ops Non-Variable Order Processing Costs [Euros] 4
Shelf Lif Requirements s
Standard Shelf ua when pr reaches country months]Conmainger Sie r d b n C customer [months]
y'ur" a*'" pnt C"sn
Mintmum Packaging Qntuantity
Transfer Price per dos Euros]
inventory SonRce Level Desired Dow
Desired Supply Bur [months]
Does this product require a extra safely stock due to
emergency outbreks? N
Cotagner Size and Shipment Codh informahon
Do you reclw shipments in doirn size shipping
containers depending on the order quantity? Ye.
Container ainn
Maxmu ds sripping container S 0,0Non-Vaiable oat [burms] 6.ON slo
Do yu pefe shipment of full boxes?U I.e Peox i
Do you prefe shipments of full Containers?
Do you pEfer shipret of full baches? M
Doses per Batch Size?
Roundin Rul's
Round Down
If order size Round up if
is this order size Is
percet this percent
grader than less than a















































































































9.2. Data for Case 2: Short Sellable Shelf Life
Country and Product Data for Short Sellable Shelf Life
Date on this sheet shoukd be reviewed at lest every three nontft to
confinm It's accurac
Data on this sheet was last re"iewed on
In-ountry Release Time and Costs
In County Release time months)
Non-Vadae inountry ease costs per Order [Euros]
Tech Ops Times and Coats
lime Fence months
Tech Ops Non-Vari Order Processing Costs [Euros) 4 00C
Shalt Life Requirements
Standard Shelf Ulfe when p ut reaches countr Imonths]
Hemaining Shelf In& reqred by customer [MOnths
Annual Imentory Holdng Cost
Minimum Packaging Quantity
Transfer Price per dos [Euros]
Irentory Sonce LDesired
Desired Supply Bule [months
Does this product requWire a extra safety stock due to
emergency outbreaks?
Container Size and Shipment Cost Inlormalon
Do you recieve shipments in diflerent size shipping
containers depending on the order quantity? No
Only
Container
Maximum doses h 'f container s0AW
e P7-go t [uros $0
D ou shipmnents of Juli boxes? lye&
Lass Per BoI 5
Do you prefer shipments of fU Containers? W
Do you prefer shipments of fu batches? Yes
Doses per Batch Size?
Rimirin Riles
Round Down
If order size Round up If
Is this order size is
percent this percent
greater than less than a
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9.3. Data for Case 3: Seasonal and Market Trends
Country and Product Data for Seasonal and Market
I Trends
confir It's accuracy
Data on this sheet was last reviewed on
In-Country Release Time and Costs
In County Release Time months) C.
Non-Variable n-Country e Costs per Order [Euros]
Tech Ops Times and Costs
lime Fence [months]
Tech Op Nn-Varie r Processing Costs {Euros]
Shelf .ife Requirements
Standard Shell ULe when prdc reaches country [months]
Remaining shelf Ite required by customer [monthsj
Annual Imentory Holding Cost
Minimum Packaging Ouantity
Transfer Price per dose [Euros]
lmentory Senice Le el sired
Desired Supply Buller [months]
Does this product require a extra safety stock due to
emr ncy outbreaks? No
Container Size and Shipment Cost Information
Do you recieve shipments in differnt size shipping
containers depending on the order quantity? No
Only
Maximum doses Er shippng container 200ta p00w
Non-Variable cost [Euros) 60
Do you rier shipments offull boxes?Ye
Ioses Per Box




if order size Round up it
is this order size is
percent this percent
greater than less than a
a ll unit RA unit
Box : WA ,
Container
s~c
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